Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 130 of 6351
-
Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
Disease control Recruiting nowThis is a phase 2 open-label study to test the safety and effectiveness of combining pembrolizumab and bendamustine in patients with relapsed (cancer that has come back or started getting worse) or refractory (cancer that is not responding or has stopped responding to treatment) …
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a One-Time gene therapy tame wet AMD for years?
Disease control By invitation onlyThis is a prospective study designed to evaluate the long-term safety and efficacy of ABBV-RGX-314. Eligible participants are those who were previously enrolled in a clinical study of nAMD in which they received suprachoroidal space (SCS) administration of ABBV-RGX-314. Enrollmen…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New hope for Hard-to-Treat breast cancer: targeted pill combo in final testing
Disease control OngoingThe purpose of this study is to complement Study CBYL719C2301 (SOLAR-1) and obtain more comprehensive data on the efficacy and safety of alpelisib (BYL719) in combination with fulvestrant compared with placebo plus fulvestrant in men or postmenopausal women with HR-positive, HER2…
Phase 3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
Can a Lab-Grown vein with a Built-In valve fix damaged leg veins?
Disease control CompletedThis study aims to evaluate the safety (incidence of adverse events including serious adverse events and clinical significant laboratory abnormalities) of personalized tissue engineered veins (P-TEV) with valves implanted in patients with severe chronic venous insufficiency (CVI)…
Phase 1 • Sponsor: Verigraft AB • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could stem cells slow a fatal brain disease?
Disease control OngoingMultiple system atrophy (MSA) is a rare, rapidly progressive, and invariably fatal neurological condition characterized by autonomic failure, parkinsonism, and/or ataxia. There is no available treatment to slow or halt disease progression. The purpose of this study is to assess o…
Phase 2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Engineered T-Cells take aim at Hard-to-Treat pancreatic cancer
Disease control Stopped earlyThis phase I trial evaluates the side effects and best dose of mesothelin-specific T-cells (FH-TCR-Tᴍsʟɴ) in treating patients with pancreatic ductal adenocarcinoma that has spread to other places in the body (metastatic). Chemotherapy drugs, such as cyclophosphamide and fludarab…
Phase 1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
New shot could tame rare 'Fat Blood' disease and prevent pancreatitis
Disease control CompletedThe purpose of AROAPOC3-3001 is to evaluate the efficacy and safety of ARO-APOC3 (plozasiran) in adult participants with familial chylomicronemia syndrome (FCS). Participants who have met all eligibility criteria will be randomized to receive 4 doses of plozasiran or matching pla…
Phase 3 • Sponsor: Arrowhead Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Triple attack on tough breast cancer: combining targeted therapies may improve outcomes
Disease control CompletedThis study is to find out that if HER-2 positive and HR positive patients could benefit from trastuzumab and pertuzumab combined with palbociclib and endocrine therapy.
Phase 2 • Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Gene therapy aims to stop painful swelling attacks in hereditary angioedema
Disease control OngoingThis study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).
Phase 1/2 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Can a Patient's own immune cells fight advanced cancer?
Disease control Recruiting nowThis study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with advanced solid tumors. Autologous TILs are expanded from tumor resections or biopsies and infused i.v. into the patient after NMA lymphodepletion treatment with hy…
Early phase 1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Nanoparticles boost radiation to fight head and neck cancer in elderly
Disease control Recruiting nowThis is a global, open-label, randomized, 2-arm, Investigator's choice Phase 3 (Pivotal Stage) study to investigate the efficacy and safety of JNJ-90301900 (NBTXR3) / radiation therapy (RT)±cetuximab versus RT±cetuximab in treatment-naïve, platinum-ineligible, elderly participant…
Phase 3 • Sponsor: Johnson & Johnson Enterprise Innovation Inc. • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Simple blood test could spot hidden cancers before symptoms start
Diagnosis OngoingThis is a prospective, multi-center interventional study of the GRAIL multi-cancer early detection (MCED) test with return of test results for participants enrolled through healthcare systems in North America. The purpose of this study is to evaluate the safety and performance of…
Sponsor: GRAIL, Inc. • Aim: Diagnosis
Last updated Jun 27, 2026 12:33 UTC
-
Can a short immunotherapy course shrink early breast tumors before surgery?
Disease control OngoingThis study aims to evaluate the efficacy and safety of preoperative Durvalumab in patients with early small (cT1N0) triple negative breast cancer tumors. This study will recruit patients with early HR-negative breast cancer all invasive types (ER \< 10%, PR \< 10%, HER2 negative)…
Phase 2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Bleeding stroke drug shows promise in Fast-Action trial
Disease control OngoingThe objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The centra…
Phase 3 • Sponsor: Joseph Broderick, MD • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New hope for advanced stomach cancer: experimental combo targets HER2-positive tumors
Disease control OngoingThis study is being done to find out if zanidatamab, when given with chemotherapy plus or minus tislelizumab, is safe and works better than trastuzumab given with chemotherapy. The patients in this study will have advanced human epidermal growth factor 2 (HER2)-positive stomach …
Phase 3 • Sponsor: Jazz Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New shot could cut bleeding episodes for hemophilia a patients
Disease control CompletedThis study is investigating how Mim8 works compared to other medicines in people with haemophilia A, who either have inhibitors or do not have inhibitors. Mim8 is a new medicine that will be used for prevention of bleeding episodes. Mim8 works by replacing the function of the mis…
Phase 3 • Sponsor: Novo Nordisk A/S • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New hope for severe lung disease: drug delays death and hospitalization
Disease control CompletedThe objective of this study is to evaluate the effects of sotatercept (MK-7962, formerly called ACE-011) treatment (plus maximum tolerated background pulmonary arterial hypertension \[PAH\] therapy) versus placebo (plus maximum tolerated background PAH therapy) on time to first e…
Phase 3 • Sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Major study tests moderna vaccine in High-Risk groups
Vaccine CompletedThe study will evaluate the clinical efficacy of different dosing regimens of the Moderna COVID-19 mRNA vaccine (100 mcg) in preventing COVID-19 disease in people who are living with HIV or have comorbidities associated with elevated risk of severe COVID-19, with the different va…
Phase 2/3 • Sponsor: COVID-19 Prevention Network • Aim: Vaccine
Last updated Jun 27, 2026 12:23 UTC
-
New RSV shot shows promise for protecting vulnerable babies
Prevention CompletedThis study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
Phase 3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Prevention
Last updated Jun 27, 2026 12:30 UTC
-
New pill may cut transfusions for thalassemia patients
Disease control OngoingThe primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
Phase 3 • Sponsor: Agios Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC